

FINAL PROGRAMME



EUROPEAN
HIV HEPATITIS CO-INFECTION (EHHC)
CONFERENCE

10–11 December 2015

QEII Centre

LONDON

CONFERENCE SPONSORS 2015

abbvie

 Bristol-Myers Squibb

 GILEAD

 MSD



12 CPD
Unique Reference No:
99117

C O N T E N T S

Programme Summary	3	Conference Information	10
Pre-conference Programme	4	Exhibition Floor Plan	11
Programme	5–8	Programme Committee	12
Sponsors' Workshop / Satellite Symposia	9	Speaker Biographies	13–18
		Sponsors and Exhibitors	19

Dear Delegate

Welcome to the [European HIV Hepatitis Co-infection \(EHHC\) Conference](#) in London, UK. The conference has been led by a Programme Committee comprising representatives from partner organisations from across Europe.

I would like to extend my grateful thanks to the committee members for their efforts in preparing an excellent programme for this conference.

We are especially delighted that a number of eminent international speakers are joining us in London to share their latest research and we thank them for their invaluable contributions in helping to make the conference, what promises to be, a great success.

Finally, we would like to thank our sponsors for their support, which assists greatly with the costs incurred in organising this event.


We very much hope you enjoy the programme and find it relevant to both your educational and practical needs.

Yours sincerely,

Sanjay Bhagani

Dr Sanjay Bhagani

Chair, BHIVA Hepatitis Society, a subcommittee of BHIVA



EHHC Conference: **QEII Centre**, Broad Sanctuary, London SW1P 3EE

Registration	Sanctuary Foyer , Ground Floor
Pre-conference Clinical Course	Churchill , Ground Floor
Pre-conference Nurses' Course	Gielgud , Second Floor

EHHC Conference

Lecture Theatre	Churchill , Ground Floor
Lunchtime Workshop	Gielgud , Second Floor
Satellite Symposia	Churchill , Ground Floor
Exhibition	Pickwick , First Floor
Lunch and Refreshments	Pickwick , First Floor
Speakers' Presentation Preview Room	Control Room , First Floor
Sponsors Rehearsal Room	Nightingale , Ground Floor
Welcome Reception	Pickwick , First Floor

12 CPD Credits

Unique reference number: **99117**

THURSDAY 10 DECEMBER 2015

0900–1845	Registration and Exhibition open at QEII Centre
0925–1130	Pre-conference Clinical Course
0925–1135	Pre-conference Nurses' Course

EHHC Conference

1145–1930	Exhibition open at QEII Centre
1140–1225	Bristol-Myers Squibb Lunchtime Workshop
1145–1235	Lunch
1235–1245	Introduction
1245–1345	MSD Satellite Symposium
1345–1435	Plenary Session 1
1435–1500	Refreshments
1500–1550	Plenary Session 2
1550–1640	Plenary Session 3
1640–1700	Afternoon tea
1700–1745	Clinical case presentations
1745–1845	Bristol-Myers Squibb Satellite Symposium
1845–1930	Welcome Reception

FRIDAY 11 DECEMBER 2015

0800–1645	Registration and Exhibition open at QEII Centre
0830–0930	Gilead Sciences Satellite Symposium
0930–1030	Plenary Session 4
1030–1100	Invited Lecture 1
1100–1130	Morning coffee
1130–1230	Plenary Session 5
1230–1300	Invited Lecture 2
1300–1400	Lunch and exhibition
1400–1600	Plenary Session 6
1600–1640	Two debates
1640–1645	Close

T H U R S D A Y 1 0 D E C E M B E R 2 0 1 5

PRE-CONFERENCE CLINICAL COURSE

0900–1130	<i>Registration open at QEII Centre</i>
0925–0930	Welcome address <i>from the Co-Chairs</i> Dr Ranjababu Kulasegaram <i>St Thomas' Hospital, London, UK</i> Dr Andrew Freedman <i>Cardiff University School of Medicine, UK</i>
0930–1000	Basics of hepatitis B diagnostics Dr Emma Page <i>Leeds Teaching Hospitals NHS Trust, UK</i>
1000–1030	Overview of biomarkers for viral evolution and liver disease progression in hepatitis B and hepatitis C Dr Philippe Halfon <i>Hôpital Européen Marseille, France</i>
1030–1100	Low-level transaminitis in an HIV-mono-infected patient Dr Emmanuel Tsochatzis <i>University College London, UK</i>
1100–1130	Exploring viral kinetics in hepatitis Professor Carlo-Federico Perno <i>Università degli Studi di Roma Tor Vergata, Italy</i>

PRE-CONFERENCE NURSES' COURSE

0925–0930	Welcome address <i>from the Co-Chairs</i> Mr Ricky Gellissen <i>National HIV Nurses Association (NHVNA)</i> Ms Sally Bufton <i>British Association for the Study of the Liver Nurse Forum</i>
0930–0955	An overview of blood results, interpretation and what this means for the CNS in clinic Mrs Janet Catt <i>Royal Free London NHS Trust, UK</i>
0955–1020	Patients' experience of hepatitis C Dr Magdalena Harris <i>London School of Hygiene and Tropical Medicine, UK</i>
1020–1045	Hepatitis C and cirrhosis Ms Lynda Greenslade <i>Royal Free London NHS Trust, UK</i>
1045–1110	Acute hepatitis C infection in HIV-positive MSM partner notification and issues of re-infection Mr Ricky Gellissen <i>Imperial College Healthcare NHS Trust, London, UK</i> Dr Matthew Grundy-Bowers <i>City University London, UK</i>
1110–1135	The arguments for treating promptly vs waiting for eligibility for DAAs Dr Emma Thomson <i>University of Glasgow Centre for Virus Research, UK</i>

The Pre-conference Nurses' Course is jointly organised by the National HIV Nurses Association (NHVNA) and the British Association for the Study of the Liver Nurse Forum (BASLNF)



T H U R S D A Y 1 0 D E C E M B E R 2 0 1 5

EUROPEAN HIV HEPATITIS CO-INFECTION CONFERENCE

1100–1845 *Registration open at QEII Centre*

1145–1235 *Lunch*

1140–1225 **Bristol-Myers Squibb Lunchtime Workshop** *(see page 9 for further details)*

1235–1245 **Introduction and Welcome**
Dr Sanjay Bhagani *Chair, EHHC Conference Steering Committee*
The Rt Hon Lord Fowler *BHIVA Patron*

1245–1345 **MSD Satellite Symposium** *(see page 9 for further details)*

1345–1435 **Plenary Session 1:**
Chairs: Professor Mark Nelson *Chelsea and Westminster Hospital, London, UK*
Dr Emma Thomson *University of Glasgow, UK*

1345–1415 **State of the art in hepatitis C treatment**
Professor Graham Foster *Queen Mary University of London, UK*

1415–1435 **Should we be doing baseline resistance testing?**
Professor Jean-Michel Pawlotsky *Hôpital Henri Mondor, Créteil, France*

1435–1500 *Refreshments*

1500–1550 **Plenary Session 2:**
Chairs: Dr Andrew Ustianowski *North Manchester General Hospital, UK*
Dr Janice Main *Imperial College Healthcare NHS Trust, London, UK*

1500–1530 **Hepatitis C treatment failure: what next?**
Dr Ashley Brown *Imperial College Healthcare NHS Trust, London, UK*

1530–1550 **Pharmacoeconomics of hepatitis C treatment**
Dr Andrew Hill *University of Liverpool, UK*

1550–1640 **Plenary Session 3:**
Chairs: Dr Graham Cooke *Imperial College Healthcare NHS Trust, London, UK*
Dr Stefan Mauss *Center for HIV and Hepatogastroenterology, Düsseldorf, Germany*

Data from real-life cohorts

France: Professor Lionel Piroth *Centre Hospitalier Universitaire, Dijon, France*
Germany: Dr Stefan Mauss *Center for HIV and Hepatogastroenterology, Düsseldorf, Germany*
UK: Dr Andrew Ustianowski *North Manchester General Hospital, UK*
Spain: Dr Karin Neukam *Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain*
Ukraine: Dr Sergii Filippovych *Aids Alliance, Kiev, Ukraine*

Panel Discussion

T H U R S D A Y 1 0 D E C E M B E R 2 0 1 5

EUROPEAN HIV HEPATITIS CO-INFECTION CONFERENCE

1640–1700 *Afternoon tea*

1700–1745 **Clinical case presentations**

Reviewers and Panellists

Dr Gary Brook *North West London Healthcare NHS Trust, UK*

Dr Ranjababu Kulasegaram *St Thomas' Hospital, London, UK*

Dr Patrick Ingiliz *Medical Center for Infectious Disease, Berlin, Germany*

Treatment of recurrent hepatitis C infection after liver transplantation in an HIV-positive patient

Dr Emma Hathorn *University Hospitals Birmingham NHS Foundation Trust, UK*

Use of resistance testing for salvage DAA therapy

Dr Federico Garcia *CHUG Hospital Universitario San Cecilio, Granada, Spain*

Hep today, gone tomorrow

Dr James Millard *Brighton and Sussex Medical School, UK*

Nephrotic syndrome in a patient with HCV/HIV co-infection

Dr Ramona Malek *Imperial College Healthcare NHS Trust, London, UK*

1745–1845 **Bristol-Myers Squibb Satellite Symposium** *(see page 9 for further details)*

1845–1930 **Welcome Reception**

F R I D A Y 11 D E C E M B E R 2015

EUROPEAN HIV HEPATITIS CO-INFECTION CONFERENCE

0800–1645	<i>Registration open at QEII Centre</i>
0800–0830	Breakfast sponsored by Gilead Sciences  GILEAD
0830–0930	Gilead Sciences Satellite Symposium (see page 9 for further details)
0930–1030	Plenary Session 4: Hepatitis B Chairs: Professor Karine Lacombe <i>Hôpital Saint-Antoine, Paris, France</i> Dr David Chadwick <i>James Cook University Hospital, Middlesbrough, UK</i>
0930–1000	Hepatitis B: new treatments, new targets and possible cure Professor Fabien Zoulim <i>Hospices Civils de Lyon, France</i>
1000–1030	Hepatitis B/liver cancer: pathogenesis, screening and treatment Dr David Pinato <i>Imperial College Healthcare NHS Trust, London, UK</i>
1030–1100	Invited Lecture 1: Chairs: Dr Emma Devitt <i>Chelsea and Westminster Hospital, London, UK</i> Professor Lionel Piroth <i>Centre Hospitalier Universitaire, Dijon, France</i> What happens to the liver after cure? Dr Vincent Mallet <i>Université Paris Descartes, France</i>
1100–1130	<i>Morning coffee</i>
1130–1230	Plenary Session 5: Hepatitis E Chairs: Dr Emma Page <i>Leeds Teaching Hospitals NHS Trust, UK</i> Dr Christoph Boesecke <i>University of Bonn, Germany</i>
1130–1200	Epidemiology, transmission and treatment Dr Antonio Rivero-Juárez <i>Instituto Maimónides de Investigación Biomédica de Córdoba, Spain</i>
1200–1230	Diagnosis Dr Harry Dalton <i>Royal Cornwall Hospital, Truro, UK</i>
1230–1300	Invited Lecture 2: Chairs: Dr Ed Wilkins <i>North Manchester General Hospital, UK</i> Dr David Asboe <i>Chelsea and Westminster Hospital NHS Foundation Trust, London, UK</i> Unique issues of HCV in IVDU populations in Central and Eastern Europe Professor Mojca Maticic <i>University Medical Centre Ljubljana, Slovenia</i>
1300–1400	<i>Lunch and exhibition</i>

F R I D A Y 1 1 D E C E M B E R 2 0 1 5

EUROPEAN HIV HEPATITIS CO-INFECTION CONFERENCE

- 1400–1600 **Plenary Session 6: Acute HCV, TasP and Access**
Chairs: Mr Robert James *Birchgrove, Brighton, UK*
Professor Clifford Leen *Western General Hospital, Edinburgh, UK*
- 1400–1430 **Counselling, psychology and behaviour / lifestyle changes**
Dr David Stuart *Chelsea and Westminster Hospital, London, UK*
- 1430–1500 **Recent data in treatment of acute hepatitis C**
Dr Christoph Boesecke *University of Bonn, Germany*
- 1500–1530 **Treatment as prevention: modelling data**
Dr Natasha Martin *University of California, San Diego, USA*
- 1530–1600 **Access to hepatitis C treatment**
Mr Svilen Konov *European AIDS Treatment Group (EATG)*
- 1600–1640 **Two debates**
Chair: Dr Chloe Orkin *Barts Health NHS Trust, London, UK*
- **Should HIV-positive patients be prioritised for hepatitis C treatment?**
For the motion:
Dr Sanjay Bhagani *Royal Free London NHS Trust, UK*
Against the motion:
Professor Mark Nelson *Chelsea and Westminster Hospital, London, UK*
 - **Separate clinical trials for co-infected patients are a necessity**
For the motion:
Professor Karine Lacombe *Hôpital Saint-Antoine, Paris, France*
Against the motion:
Dr Patrick Ingiliz *Medical Center for Infectious Diseases, Berlin, Germany*
- 1640–1645 **Close**
Dr Sanjay Bhagani *Chair, EHHC Conference Steering Committee*

The Lunchtime Workshop will be located in the **Gielgud, Second Floor**
Satellite symposia will be held in the **Churchill, Ground Floor**

THURSDAY 10 DECEMBER 2015

1140–1225

Bristol-Myers Squibb Lunchtime Workshop **Mapping out the road to viral hepatitis and HIV cure**

Chair: Professor Clifford Leen *Western General Hospital, Edinburgh, UK*

Introduction

Professor Clifford Leen *Western General Hospital, Edinburgh, UK*

Strategies for HIV cure

Dr Sarah Fidler *Imperial College Healthcare NHS Trust, London, UK*

Functional cure for viral hepatitis - are we there yet?

Dr Ivana Carey *King's College London, UK*

Discussion: questions and answers from the audience

Professor Clifford Leen *Western General Hospital, Edinburgh, UK*

1245–1345

MSD Satellite Symposium **Clinical conundrums in co-infection**

Chair: Dr Andrew Ustianowski *North Manchester General Hospital, UK*

Professor John Dillon *Ninewells Hospital, Dundee, UK*

Dr Laura Waters *Mortimer Market Centre, London, UK*

Ms Fiona Marra *Gartnavel General Hospital, Glasgow, UK*

1745–1845

Bristol-Myers Squibb Satellite Symposium **Is HCV treatment in HIV/HCV co-infection really that simple?**

Chair: Professor Mark Nelson *Chelsea and Westminster Hospital, London, UK*

Dr Stefan Mauss *Centre for HIV and Hepatogastroenterology, Düsseldorf, Germany*

Professor Jean-Michel Pawlotsky *Hôpital Henry Mondor, Créteil, France*

Dr Kosh Agarwal *King's College Hospital NHS Foundation Trust, London, UK*

FRIDAY 11 DECEMBER 2015

0830–0930

Gilead Sciences Satellite Symposium **Screening for blood-borne viruses: what could we do better?**

Chair: Mr Charles Gore *The Hepatitis C Trust, UK*

Dr Chloe Orkin *Barts Health NHS Trust, London, UK*

Professor Karine Lacombe *Hôpital Saint-Antoine, Paris, France*

Registration

EHHC Conference: The registration fee gives access to the scientific sessions of the EHHC Conference including satellite symposia. All refreshments and lunches throughout the conference are included in the registration fee. Registration opens from 1100 on Thursday 10 December 2015 and from 0800 on Friday 11 December 2015.

Pre-conference Clinical Course and Nurses' Course: Registration is on a complimentary basis. However, if you fail to turn up at the event, your cheque will be cashed or your credit card charged £50. Registration gives access to the scientific sessions of the applicable course. Welcome refreshments are included. Please note that lunch is not included as part of registration for the courses. Registration for the courses opens from 0900 on Thursday 10 December 2015.

Welcome Reception

The Welcome Reception immediately follows the conference programme at 1845–1930 on Thursday 10 December and will take place in the exhibition area located in the Pickwick Suite on the first floor.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, social events and satellite symposia). The conference will be allocated a maximum of 6 CPD credits per conference day.

CPD Accreditation: Credits attributed & unique reference number		
EHHC Conference	10 Credits	99117
Pre-conference Clinical Course	2 Credits	99117
Pre-conference Nurses' Course	2 Credits	99117

Accommodation

Please note that the registration fee does not include accommodation. A list of hotels and rates is available on the BHIVA website (www.bhiva.org). Please note that HotelMap has been appointed the official conference accommodation bureau. HotelMap is a web-based service that provides live details of hotel deals directly from hotels near to our event venue. On booking, you will receive a hotel reservation booking reference number. Payment will need to be made by you directly to the hotel.

Book online: www.bhiva.org · Queries: **HotelMap** · Telephone: **0207 420 4987**

Cloakroom

A staffed cloakroom is available at the QEII Centre. All belongings are left at the owner's risk. The QEII Centre and EHHC do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom areas.

Conference Venue

QEII Centre · Broad Sanctuary · Westminster · London SW1P 3EE · t: (44 (0)20 7222 5000 · w: qeicc.co.uk

The conference venue is a short walk from Westminster or St James's Park underground stations. Please see the map for the location of these stations in relation to the QEII Conference Centre.


Westminster and St James's Park underground stations are easily accessible from King's Cross, St Pancras (Eurostar) and Victoria main-line rail stations and can be accessed by the Jubilee line or the Circle and District lines. The journey from these main-line stations to Westminster or St James's Park underground stations takes approximately 10 minutes.

There are also good links to the city centre from both Heathrow and Gatwick airports. Journeys by either Heathrow or Gatwick Express take about 1 hour.

There are four car parks near to the conference venue. For further information please visit www.ncp.co.uk


Please note that the conference venue is located within the London Congestion Charge Zone.





KEY TO EXHIBITORS

Stand 1.	AbbVie Limited
Stand 2.	MSD
Stand 3.	Gilead Sciences Ltd
Stand 4.	European AIDS Treatment Group
Stand 5.	UK Community Advisory Board (UK-CAB)
Stand 6.	Bristol-Myers Squibb Pharmaceuticals Ltd
Stand 7.	MSD Medical



EHHC Programme Committee 2015

Dr Sanjay Bhagani (Chair)	<i>Royal Free Hospital, London, UK</i>
Professor Giovanni Guaraldi (SIMIT)	<i>University of Modena, Italy</i>
Dr Mark Hudson (BASL)	<i>Freeman Hospital, Newcastle, UK</i>
Dr Robert James (UK-CAB)	<i>Birchgrove, Brighton, UK</i>
Mr Damian Kelly (EATG)	<i>European AIDS Treatment Group</i>
Dr Ranjababu Kulasegaram (BHIVA)	<i>St Thomas' Hospital, London, UK</i>
Professor Karine Lacombe (ANRS)	<i>Hôpital Saint-Antoine, Paris, France</i>
Professor Clifford Leen (BHIVA)	<i>Western General Hospital, Edinburgh, UK</i>
Dr Chloe Orkin (BHIVA)	<i>Barts Health NHS Trust, London, UK</i>
Dr Juan Macias (GEHEP)	<i>Hospital Universitario de Valme, Sevilla, Spain</i>
Dr Stefan Mauss (DAIG)	<i>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany</i>
Professor Mark Nelson (BHIVA)	<i>Chelsea and Westminster Hospital, London, UK</i>
Dr Juan Antonio Pineda (GEHEP)	<i>Hospital Universitario de Valme, Sevilla, Spain</i>
Professor Massimo Puoti (SIMIT)	<i>Universita degli Studi di Brescia, Italy</i>
Professor Lionel Piroth (ANRS)	<i>Centre Hospitalier Universitaire, Dijon, France</i>
Professor Jürgen Rockstroh (DAIG)	<i>University of Bonn, Germany</i>
Dr Andrew Ustianowski (BVHG)	<i>North Manchester General Hospital, UK</i>



Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free Hospital, London and Honorary Senior Lecturer in Infectious Diseases at University College London. After completing his postgraduate training in Infectious Diseases and Internal Medicine in London, he joined the Royal Free Hospital as a Consultant Physician where he established and is the current lead of a multi-disciplinary HIV/hepatitis co-infection service. This is a tertiary referral service at the fore-front of service delivery in all aspects of HIV/viral hepatitis co-infection, ranging from access to phase 2/3 clinical trials for new agents to joint liver transplant assessment and post-transplant care. His team's research interests include epidemiological, virological and clinical aspects of acute HCV amongst HIV-positive MSM, use of non-invasive tests for liver assessment in resource-rich and resource-limited settings, implementation and clinical research in the management of viral hepatitis and HIV co-infection in resource-limited settings, and phase 2/3 clinical trials for new agents for treating HCV and HBV. Sanjay is the current chair of the British HIV Association's Viral Hepatitis Group and serves on the HIV/hepatitis guidelines committee for both the British HIV Association and the European AIDS Clinical Society. He serves on the editorial boards of *AIDS Research and Therapy* and *BMC Hepatology, Medicine and Policy* and is a trustee at AIDSOrphan. Sanjay has a passion for teaching and is currently on the steering committee for the EACS Advanced HIV course and a member of the board of examiners for the Diploma in HIV Medicine, UK.

Christoph Boesecke completed his medical studies at Charité University in Berlin and received his Doctorate in Medicine from the University of Hamburg for his research in acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now The Kirby Institute) in Sydney, Australia. Christoph is currently working as an Infectious Diseases Specialist and Clinical Research Fellow at the University of Bonn. His main areas of research are focused on co-morbidities and co-infections in HIV, particularly acute hepatitis C.

Gary Brook is Clinical Lead for HIV/GUM at Central Middlesex, Northwick Park and Ealing Hospitals, London and also maintains an interest in infectious and tropical diseases. He first became involved in viral hepatitis in the late 1980s when he wrote his MD thesis on interferon treatment for chronic hepatitis B at the Royal Free and St Mary's Hospitals London. Subsequently, as well as continuing with a research interest in hepatitis, Gary has been the lead for national and international viral hepatitis management guidelines on behalf of BHIVA, BASHH and IUSTI/WHO.

Ashley Brown is a Consultant Hepatologist at St Mary's Hospital and Adjunct Reader at Imperial College London. He studied as an undergraduate at the University of Liverpool before undertaking specialist training in liver disease, and obtaining an MD from the University of Newcastle-upon-Tyne. Ashley has a major clinical interest in viral hepatitis with a special interest in accessing care for difficult-to-reach populations. His research interest lies in novel treatments for HBV and HCV, and he serves as Chief or Principal Investigator on a large number of clinical trials. Ashley is currently Chairman of the London Joint Working Group on HCV in PWIDs, and former Chair of the British Viral Hepatitis Group. He has published numerous articles and abstracts in peer review journals and is a frequent speaker at national and international liver meetings.

Janet Catt is an Independent Non-medical Prescriber, and has had a varied nursing experience that has included oncology, haematology, palliative care and health visiting. Since 2008 she has been a Lead Nurse Specialist Practice at the Royal Free Hospital, London where she manages a team of clinical nurse specialists and leads on the development of the nursing service. As part of her role, she also researches local epidemiology in order to develop ways to improve patient pathways. Janet is a founder member of the steering group for the Interactive Summit on Hepatitis and sits on the London Joint Working Group for Substance Misuse and Hepatitis C. She is a regular speaker at international conferences.

Harry Dalton is a Consultant Gastroenterologist at the Royal Cornwall Hospital and Honorary Senior Lecturer at the European Centre for the Environment and Human Health, University of Exeter, Truro. Over the last 10 years he has been working on HEV. Harry has published many papers on this subject in diverse journals, including *New England Journal of Medicine*, *Lancet*, *Lancet Infectious Diseases*, and *Annals of Internal Medicine*. He contributed to the WHO-sponsored Global Burden of Disease project as an expert panel member on HEV. In 2011, he was awarded the Dame Sheila Sherlock Travelling Fellowship to develop collaborative links with the HEV research group in Europe.

Sergii Filippovych is Director: Treatment, Procurement and Supply Management of ICF 'International HIV/AIDS Alliance in Ukraine'. His experience in healthcare spans more than 35 years, and he has 20 years' experience in the field of HIV/AIDS treatment and prevention. He has witnessed and significantly contributed to the origin and development of treatment programs for key populations in Ukraine. Programs include but are not limited to ART, OST, STI and hepatitis treatment. Sergii headed the implementation of hepatitis C treatment services delivery to 100 HIV-positive clients of OST and now provides leadership of the project 'Scaling up accessible and effective HCV treatment with DAA through a community-engaged treatment model for the most vulnerable populations in Ukraine'.

Graham Foster is Professor of Hepatology at Queen Mary's, University of London and a Consultant at Barts Health in East London. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992. Graham has a long-standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities, and novel therapies for this disease. He leads a national study investigating community screening for viral hepatitis and supervises a laboratory research program investigating novel replication models for hepatitis C. He is the editor of the *Journal of Viral Hepatitis* and has published widely in the field of viral liver disease. He is a past President of BASL, Vice Chairman the UK Department of Health Advisory Group on Hepatitis, and a member of a number of patient advocacy groups.

Ricky Gellissen has been in HIV nursing for over 20 years in a variety of settings. In 2008 he started a newly created role as HIV & Hepatitis Co-infection Clinical Nurse Practitioner. This year he transferred to Hepatology as a Hepatitis CNS, still providing diagnosis and treatment services to patients with HIV and hepatitis co-infection. He continually seeks to promote skill and knowledge transference between HIV and hepatology services. Ricky is an Executive Committee Member of the National HIV Nurses Association (NHIVNA) and on the NHIVNA Blood-Borne Virus Working Group, which is a collaboration between NHIVNA and the British Association of the Study of the Liver Nurse Forum (BASLNF). He is also a committee member of Pan London Nurse Education and Training (PLaNET), a Pharma sponsored series of evening educational events for HIV nurses in London.

Lynda Greenslade is a liver nurse with long-standing experience in caring for patients and their families affected by liver disease. After becoming 'hooked' on hepatology as a student nurse while working on the Liver Unit at the Royal Free Hospital, London, she returned to the specialty following spells in orthopaedics and intensive care. Since then, Lynda has worked as a liver ward sister and a research nurse, working mainly in portal hypertension. In Her current role is as a Clinical Nurse Specialist in Hepatology, she mainly looks after patients with the complications of liver disease, stable cirrhosis, or newly diagnosed with liver disease and haemochromatosis. Raising awareness of liver disease both within the profession and to the wider public is also part of her role. Lynda is currently working on a project with the Marie Curie Palliative Care UCL team, looking at ways to improve end-of-life care for patients with end-stage liver disease. She is a committee member of both the British Association of the Study of the Liver Nurse Forum and the RCN Gastroenterology Forum, and enjoys teaching in the clinical area and supporting nurses new to hepatology.

Matthew Grundy-Bowers has worked in the field since 1994, and is currently the Consultant Nurse for HIV/Sexual Health at Imperial College Healthcare NHS Trust and Honorary Senior Lecturer at City University London. He completed his PhD in Public Health in 2014 having been awarded an NIHR clinical fellowship. Matthew is passionate about developing others and regularly teaches both nurses and doctors including on the Faculty of Sexual & Reproductive Health Diploma and the British Association for Sexual Health & HIV STIF competencies. He is actively involved in professional organisations and is an executive member of NHIVNA and the BASHH STIF steering committee.

Philippe Halfon is Professor of Medicine at Paris Medical College. He received his PharmD degree in 1985 from the University of Marseilles and completed training in Virology in Saint Louis Hospital and the Pasteur Institute in Paris. He received his PhD degree in 1993 and post-doctoral training in Virology at McGill University, Montreal. He received is MD degree from the University of Marseilles and completed training in Infectious Diseases. He has published over 250 peer-reviewed papers and three books, and holds four US patents. Philippe is the founder of several biotechnology companies focusing on antiviral drug discovery and development, and is currently developing one drug in HCV and two innovative drugs in the treatment of cancer stem cells. Philippe has received the Tremplin Award and is a member of the French Agency against AIDS.

Magdalena Harris is a qualitative sociologist based at the London School of Hygiene and Tropical Medicine. She conducts a programme of research, using life history and other qualitative methods, investigating the lived experience of hepatitis C, its treatment and prevention in the UK. She has published widely on hepatitis C and issues impacting people who inject drugs; providing 'expert' guidance on hepatitis C and harm reduction for institutions such as NICE and EMCDDA. Magdalena is a collaborative partner in the European Hepatitis C and Drug Use Initiative and a board member for the Hepatitis C Trust, the *International Journal of Drug Policy*, the *Journal of Hepatitis Medicine & Policy*, and the Global Congress for Qualitative Health Research.

Andrew Hill is a Senior Visiting Research Fellow at Liverpool University, specialising in treatment access issues in HIV and Hepatitis. He graduated from Oxford University, with a PhD from the University of Amsterdam. He has published several papers on the true cost of production of drugs for HIV, hepatitis B and hepatitis C.

Patrick Ingiliz is a Specialist in Internal Medicine and Infectiology. He is currently working as a consultant in the Center for Infectiology in Berlin. His main fields of interest are HIV infection and viral hepatitis coinfection. His clinical research projects are focused on acute hepatitis C infection, liver fibrosis progression and steatohepatitis in HIV infection. Patrick is actively involved in numerous trials on direct-acting agents against hepatitis C in mono- and in coinfecting subjects, and he plays an active role in several national and international research collaborations.

Svilen Konov Svilen Konov started working in the fields of HIV in 2000 and HCV in 2005. He has a degree from the London School of Hygiene and Tropical Medicine. Svilen worked at HIV i-Base as a treatment information and advice officer until 2010 and has experience in working on international projects with the European AIDS Treatment Group where he was the HCV coordinator. He has been involved in more than 100 training events both in Western, as well as Eastern Europe and Central Asia. Currently he is a director of SEVT Ltd, a company that provides consultancy services in medical and general research methodology, medical and general literature translation, editing and writing, and patient organisations and communities' relationship and development. Svilen speaks Russian, Bulgarian, Japanese, and German. His current interests are in mathematical modelling, clinical trials' design and pharmacogenomics.

Vincent Mallet is Senior Physician and Professor in the Department of Hepatology at Cochin University Hospital in Paris. He is Research Director at the Pasteur Institute in Paris and has founded a company on big-data and health care. Vincent has worked on basic and clinical aspects of liver diseases since 1999. His main interests are HBV, HCV and HEV infections in compromised hosts and the development of novel immunomodulatory therapies for hepatocellular carcinoma.

Natasha K Martin is an Associate Professor in the Division of Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Natasha is an infectious disease and economic modeller with over 15 years of experience modelling biological systems. She earned her doctoral degree in mathematical biology from the University of Oxford, and undergraduate degree in mathematics and biology from Stanford University. Following her doctorate, she worked as a postdoctoral fellow at the University of Bristol and London School of Hygiene and Tropical Medicine. Natasha's work focuses on using dynamic epidemic modelling to evaluate the impact and cost-effectiveness of HIV, HCV and HBV prevention interventions among high-risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading researchers examining the potential impact and cost-effectiveness of HCV treatment as prevention. Currently she is engaged in a number of HIV and HCV intervention evaluation trials in international settings such as Mozambique, India, Kenya, Ukraine, Mexico, Australia and the UK.

Mojca Maticic is a specialist in internal medicine and infectious diseases, with postdoctoral training at the Middlesex Hospital and Royal Free Hospital, London. She is the Head of the Viral Hepatitis Unit at the Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre, Ljubljana, and Professor of the Medical Faculty, University of Ljubljana. Mojca leads the interdisciplinary National Viral Hepatitis Expert Group in Slovenia and is a member of the HIV/AIDS Committee at the Slovene Ministry of Health. She co-authored national consensus guidelines for the management of hepatitis B and hepatitis C in Slovenia and co-organised a national healthcare network for the management of hepatitis C in people who use drugs.

Stefan Mauss specialised in internal medicine and gastroenterology at the Heinrich-Heine University in Düsseldorf. After leaving the university in 1996 he opened, as a founding member, the Center for HIV and Hepatogastroenterology, an outpatient clinic and privately based research centre. His primary research interests are complications of antiviral therapy and their management in HIV, hepatitis B and hepatitis C. In addition he focuses on treatment strategies of viral hepatitis B or C in mono- or HIV-coinfected patients. Stefan has published more than 140 original articles and reviews in international journals. He has edited numerous books on HIV and viral hepatitis including 'Hepatology – a clinical textbook', which is regularly updated and available free at www.hepatologytextbook.com.

Mark Nelson is a Consultant Physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital Medical School from where he qualified in 1986. He was appointed Consultant Physician at this hospital in 1991 where is presently the Lead for HIV in patient and day case care and is the Professor of HIV medicine at Imperial College Medical School, where he is also the Deputy Senior Tutor. He has built a large HIV practice with a special interest in HIV in patient care, co-infection with hepatitis B and C, and the clinical utility of new antiretroviral agents. He has published over 500 papers on HIV and hepatitis.

Karin Neukam is currently Research Scientist at the Valme University Hospital in Seville. She trained in pharmacy at the University of Würzburg and completed a PhD at the University of Düsseldorf, as well as a Sara Borrell postdoctoral fellowship at the Valme University Hospital, the Royal Free London NHS Foundation Trust and the University of Liverpool. Her clinical research projects are focused on real-life efficacy and safety of therapy against hepatitis C infection, hepatic security of antiretroviral therapy and liver fibrosis. Karin is the coordinator of the Spanish GEHEP and HEPAVIR multicentre collaborative national cohorts for treatment against chronic hepatitis C in patients with or without HIV infection.

Emma Page currently works as a Locum Consultant in Virology and Sexual Health at Leeds Teaching Hospitals Trust, where she has been in post for two years. She undertook her specialist training at Chelsea and Westminster Hospital London during which time she completed an MD(res) at Imperial College on the immunology of HIV and hepatitis C. Her main clinical and research interest remains HIV and hepatitis co-infection.

Jean-Michel Pawlotsky is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and Delta and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and Director of the Academic Department 'Viruses, Immunity and Cancers' (INSERM U955). Jean-Michel has been the Secretary General of EASL (2005–2009), and an Associate Editor of Hepatology (2001–2006). He is currently an Associate Editor of Gastroenterology. He has published over 450 articles and book chapters in his areas of expertise and given over 500 invited lectures at international meetings.

Carlo-Federico Perno is Professor of Virology at the University of Rome 'Tor Vergata', and Director of the Unit of Molecular Virology at the Tor Vergata University Hospital, Rome. He also works as Consultant of Clinical Virology at the Spallanzani Hospital for Infectious Diseases, Rome. He gained his MD from the University of Rome in 1980, and graduated in oncology in 1983. From 1986 to 1989 he worked as Research Fellow at the National Cancer Institute, Bethesda, Maryland, where he collaborated in the discovery and clinical application of the first antiviral drugs used in the therapy of HIV infection, including AZT, ddC, d4T and ddI. Carlo-Federico has published more than 470 international scientific articles mostly concerning antiviral therapy. In 2001 the European Community awarded him the Descartes Award for excellence in the antiviral field. He has major expertise in antiviral therapy, clinical interpretation and therapeutic application of antiviral resistance testing. Carlo-Federico leads a group of internationally recognised researchers funded by numerous grants from Italian institutions, the European Community, and private institutions.

David James Pinato is an NIHR Academic Clinical Lecturer in Medical Oncology at Imperial College London. Since graduating in Medicine at the University of Piemonte Orientale (Italy), he has devoted his research efforts to studying the role of inflammation as a molecular mechanism underlying the progression of Hepatocellular Carcinoma (HCC). His studies, supported by international collaborations, eventually led to the qualification of novel prognostic and predictive biomarkers in HCC. David completed his research training being awarded a Masters of Research in Translational Medicine and a PhD in Experimental Medicine. He has developed considerable experience in translational oncology within the specific setting of early-phase clinical trials. He has trained in Medical Oncology as part of the Royal Marsden Hospital rotation, having migrated to Imperial College in April 2015 to take up his Clinical Lectureship. He was awarded the European School of Oncology fellowship in 2008 and the Fulbright Visiting Research Scholar Fellowship in 2010. He is supported by grants from the Academy of Medical Sciences and Action Against Cancer, and lectures internationally in the field of molecular oncology with a specific interest in drug resistance in HCC.

Lionel Piroth has been involved in clinical care and research in HIV and hepatitis viruses in France since the mid-1990s. He is Professor of Infectious Diseases at the University of Burgundy and Physician at the Hospital of Dijon, and also actively participates in trials of antiretrovirals and other anti-infective agents. Lionel has co-authored the French Recommendations on the Management of Hepatitis Co-infection in People Living with HIV for eight years.

Massimo Puoti is a Specialist in Gastroenterology and in Infectious Disease. From November 2010 he has been the Director of the Infectious Diseases Department of the AO Ospedale Niguarda Cà Granda, the largest hospital in Milan. Massimo's main fields of research are hepatitis viruses and HIV infections.

Antonio Rivero-Juarez qualified in Veterinary Science, and has worked in the Laboratory of Infectious Diseases at the Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) since 2010, in the field of HIV and hepatotropic virus co-infection (hepatitis C and hepatitis E). He gained his PhD in 2013, and was awarded with the Extraordinary Award of the University of Córdoba (Spain) for contributions to the field of HIV/HCV co-infection. Antonio has published more than 50 papers in the last 5 years, and is an External Investigator Assistant in the FDA (USA) and Saint Louis Hospital (France).

David Stuart is the Substance Use Lead at 56 Dean Street, addressing sexualised drug use by gay men (the practice commonly referred to as 'ChemSex'). He has been involved in the development of London's pioneering services Antidote, Club Drug Clinic and CODE clinic, and has been instrumental in placing ChemSex issues firmly on international Public Health agendas. David is also the curator of the Dean Street Wellbeing programme, a series of community engagement events designed to mobilise and engage populations in action and dialogue on topical and challenging social issues that impact sexual health and wellbeing.

Emma Thomson is a Clinical Senior Lecturer and Consultant in Infectious Diseases at the Queen Elizabeth University Hospital in Glasgow and St Mary's Hospital, Imperial College London. She is responsible for the HIV/HCV co-infection treatment service in Glasgow and runs a research lab at the MRC University of Glasgow Centre for Virus Research that focuses on understanding immunity to hepatitis C. Emma is funded by a clinical fellowship from the Wellcome Trust and as a co-investigator on the MRC STOP HCV consortium.

Emmanuel Tsochatzis is a Senior Clinical Lecturer and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital, London. His main research interests include NAFLD, cirrhosis and portal hypertension, non-invasive assessment of liver fibrosis and loco-regional treatments for HCC. Emmanuel is the author of more than 100 papers in peer-reviewed journals. He was awarded the Rising Star in Gastroenterology Award by UEG in 2014.

Andrew Ustianowski is a Consultant Physician in Infectious Diseases at the North Western Regional Infection Unit, North Manchester General Hospital, which is one of the largest treatment centres for HCV in the UK (and one of the largest for HIV and HBV). He is Chair of the British Viral Hepatitis Group, has been part of guideline writing committees for BHIVA and other bodies, lectures widely on hepatitis, HIV and related topics, and is part of several national and international educational steering groups. He has been a member of the NHS England Clinical Reference Group for Infectious Diseases and for HCV. Andrew graduated from Guy's Hospital, London, and subsequently trained in infectious diseases, tropical medicine, HIV and general medicine in the London region.

Fabien Zoulim obtained his MD in Gastroenterology and Hepatology from Lyon Medical School in 1991. He also has a PhD in molecular and cellular biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He has been a Professor of Medicine at Lyon I University since 1997. Fabien is currently the Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology at INSERM Unit 1052 where he is leading the team on antiviral therapy of viral hepatitis. He has served as an Associate Editor for the *Journal of Hepatology* and is currently Associate Editor for *Gut*. He also served as an expert in the microbiology study section of the INSERM and ANRS, and in different national and international committees. He has also been a governing board member of the European Association for the Study of the Liver (EASL). He is coordinating the national HBV cure program at ANRS. Fabien received the William Prusoff award of the International Society for Antiviral Research in recognition of his work in the field of HBV molecular biology and anti-HBV therapy. Furthermore, he has been the scientific coordinator of a European community-funded network of excellence on the management of antiviral drug resistance, and is currently involved in several European projects. He has published more than 350 articles (*H-index* 59, Web of Science).

CONFERENCE SPONSORS

AbbVie Limited

AbbVie House
Vanwall Business Park
Maidenhead
Berkshire SL6 4XE

abbvie

Bristol-Myers Squibb Pharmaceuticals Limited

Uxbridge Business Park
Sanderson Road
Middlesex UB8 1DH

 **Bristol-Myers Squibb**

MSD Limited

Hertford Road
Hoddesdon
Hertfordshire EN11 9BU

 **MSD**

Gilead Sciences Limited

280 High Holborn
London WC1V 7EE

 **GILEAD**

EXHIBITORS COMMERCIAL

MSD Medical

EDUCATIONAL AND CHARITABLE

European AIDS Treatment Group (EATG)
UK Community Advisory Board (UK-CAB)



EUROPEAN
HIV HEPATITIS CO-INFECTION (EHHC)
CONFERENCE

10–11 December 2015

QEl Centre

L O N D O N

F I N A L P R O G R A M M E

C O N F E R E N C E S P O N S O R S 2 0 1 5

abbvie

